Nutriband to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference

Nutriband Inc. (NASDAQ: NTRB) announced that Chairman Serguei Melnik will present at Noble Capital Markets' Emerging Growth Virtual Equity Conference on Wednesday, October 8, 2025, at 3 p.m. ET. The presentation will feature a fireside Q&A session with questions from the live virtual audience, offering investors unique access to company leadership. Registered investors can also schedule one-on-one meetings with Melnik, providing direct engagement opportunities that are crucial for understanding the company's strategic direction and growth potential.

The conference participation is particularly significant given Nutriband's focus on developing transdermal pharmaceutical products with abuse-deterrent properties. The company's lead product under development is an abuse-deterrent fentanyl patch incorporating their proprietary AVERSA technology. This technology represents an important advancement in addressing the ongoing opioid crisis by preventing abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The ability to incorporate AVERSA technology into any transdermal patch positions Nutriband at the forefront of pharmaceutical safety innovation.

Interested attendees can register for the conference at no cost through the official conference site. A video webcast of the presentation will be available on Channelchek, Noble's investor portal, and archived for 90 days on both Channelchek.com and Nutriband's website. This accessibility ensures that investors who cannot attend live can still benefit from the presentation content and strategic insights shared during the event. The archived availability for 90 days provides extended access to this important corporate communication.

The timing of this presentation comes as the pharmaceutical industry continues to address critical safety concerns surrounding opioid medications and other drugs with abuse potential. Nutriband's technology development aligns with regulatory priorities and public health initiatives aimed at reducing prescription drug abuse. Investors following the company can access additional information through the company's newsroom at https://ibn.fm/NTRB, which provides ongoing updates about corporate developments and technological advancements. The conference presentation represents an important opportunity for market participants to gain deeper understanding of Nutriband's progress and future prospects in the competitive pharmaceutical technology landscape.